Qualitative evaluation of pharmacoeconomics study
| Economics Evaluation T in adjuvant | Study Design | Data Collection | Analysis and Interpretation of results | Final Score | Total relative score |
|---|---|---|---|---|---|
| Blank | 24/26 | 27/45 | 35/48 | 86 | 72.3% |
| Chen | 23/26 | 30/45 | 37/48 | 90 | 75.6% |
| Dedes | 24/26 | 31/45 | 35/48 | 90 | 75.6% |
| Essers | 24/26 | 30/45 | 35/48 | 89 | 74.8% |
| Garrison | 24/26 | 31/45 | 36/48 | 91 | 76.5% |
| Kurian | 25/26 | 31/45 | 37/48 | 93 | 78.1% |
| Liberato | 26/26 | 33/45 | 39/48 | 98 | 82.3% |
| Lidgren | 26/26 | 34/45 | 38/48 | 98 | 82.3% |
| Millar | 25/26 | 32/45 | 35/48 | 92 | 77.3% |
| Neyt | 25/26 | 31/45 | 34/48 | 90 | 75.6% |
| NICE | 26/26 | 42/45 | 40/48 | 108 | 90.7% |
| Norum | 25/26 | 28/45 | 34/48 | 87 | 73.1% |
| Shiroiwa | 26/26 | 31/45 | 38/48 | 95 | 79.8% |
| Skedgei | 25/26 | 27/45 | 37/48 | 89 | 74.8% |
| Van Vlaenderen | 24/26 | 31/45 | 36/48 | 91 | 76.5% |
| T in MBC | |||||
| Poncet | 24/26 | 32/45 | 31/48 | 87 | 73.1% |
| Norum J | 25/26 | 33/45 | 35/48 | 93 | 78.1% |
| Elkin | 26/26 | 37/45 | 40/48 | 103 | 86.5% |
| Lidgren | 26/26 | 36/45 | 38/48 | 100 | 84% |
| NICE (2002) | 26/26 | 42/45 | 40/48 | 108 | 90.7% |